Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life:Results in Dutch Patients and Review of the Literature
Real-life data on the treatment of myelofibrosis patients with baseline thrombocytopenia with ruxolitinib are limited. We present the outcomes of thrombocytopenic Dutch patients treated within a compassionate-use program. Additionally, we performed a literature review. We conclude that treatment of patients with platelet counts of 50 to 100 3 10(9)/L with ruxolitinib is safe. Background: Ruxolitinib is an approved treatment for myelofibrosis patients, but data regarding patients with baseline thrombocytopenia are limited. The EXPAND study recently suggested tolerability of ruxolitinib, with a... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | Slot , S , Raymakers , R A P , Schaap , N , Span , L F R , Koene , H R , Kersting , S , Boekhorst , P A W T , Westerman , M , Schouten , H C & Zweegman , S 2019 , ' Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life : Results in Dutch Patients and Review of the Literature ' , Clinical lymphoma myeloma & leukemia , vol. 19 , no. 10 , pp. 624-634 . https://doi.org/10.1016/j.clml.2019.07.005 |
Schlagwörter: | Dosing / JAK2 inhibitor / Platelet count / Safety / Treatment / POLYCYTHEMIA-VERA / OPEN-LABEL / EFFICACY / MULTICENTER / CRITERIA / THERAPY |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26671280 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/8999052c-22a4-4b2e-b123-858d5edee7ee |